Endoscopic monitoring of infliximab therapy in Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 4, 2011, Pages 947-953

  Björkesten, Clas Göran Af ^a   Nieminen, Urpo ^a   Turunen, Ulla ^a   Arkkila, Perttu E ^a   Sipponen, Taina ^a   Färkkilä, Martti A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Crohn's disease; Endoscopic response; IBD; Infliximab; Mucosal healing

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG MONITORING; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952456328     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21439     Document Type: Article

References (20)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
3. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22-28. (Pubitemid 29013489)
4. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
6. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
7. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269. (Pubitemid 38552790)
8. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut. 1987;28:474-481.
9. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17:11-17. (Pubitemid 36831453)
10. Jorgensen LG, Fredholm L, Hyltoft Petersen P, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?Clin Chem Lab Med. 2005;43:403-411.
11. Cellier C, Shmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. Gut. 1994;35:231-235.
12. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034. (Pubitemid 29203012)
13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413. (Pubitemid 38182297)
14. Mary JY, Modigliani R, Groupe d'Etudes Thérapeutiques des afflections inflammatories du tube digestif (GETAID).Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut. 1989;30:983-989.
15. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
16. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769. (Pubitemid 29468216)
17. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002:122;512-530. (Pubitemid 34117002)
18. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
19. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442. (Pubitemid 43261469)
20. Frøslie KF, Jahnsen J, Moum BA, et al. IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.